Detalhe da pesquisa
1.
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.
Cancers (Basel);
16(5)2024 Feb 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38473382
2.
Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Haematologica;
101(4): e129-32, 2016 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26768689
3.
Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms.
Leuk Lymphoma;
54(10): 2226-30, 2013 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23398206
4.
Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms.
Leuk Lymphoma;
53(3): 441-4, 2012 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21883029